Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
600329
Rang in Aktien
#4374
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its... Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Republic of China. Its business activities are structured into two distinct divisions: Chinese Medicine and Western Medicine. The company's operations extend beyond its core offerings to include the production and distribution of Chinese, Western, and biological pharmaceutical items. It also engages in the wholesale and retail trade of medicines, biochemical pharmaceutical products, and everyday consumer goods, in addition to managing hospitals. Furthermore, Tianjin Pharmaceutical Da Ren Tang provides a comprehensive suite of services such as logistics, inventory management, equipment installation, and drug processing. It also offers pharmaceutical inspection, testing, and advisory services. In terms of its commercial model, the company supplies its proprietary branded medicinal products directly to wholesalers. Conversely, it acquires pharmaceuticals marketed under other brands from distributors, subsequently reselling these to other wholesale clients. Established in 1992 and based in Tianjin, People's Republic of China, the company was previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited before adopting its current name in May 2022.
Aktienkurs
$6.17
Marktkapitalisierung
$3.52B
Veränderung (1 Tag)
-0.05%
Veränderung (1 Jahr)
-1.86%
Land
CN
Handel Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329)
Kategorie
Healthcare
Operative Marge für Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329)
Operative Marge zum October 2026 TTM: 18.33%
Laut den neuesten Finanzberichten und dem Aktienkurs von Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited beträgt die aktuelle operative Marge (TTM) 18.33%. Am Ende des Jahres 2024 lag die operative Marge bei 35.13%.
Historie der operativen Marge von Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited von 2001 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 18.33% | -63.80% |
| 2025 | 50.63% | 44.12% |
| 2024 | 35.13% | 163.34% |
| 2023 | 13.34% | 12.29% |
| 2022 | 11.88% | -5.34% |
| 2021 | 12.55% | 5.55% |
| 2020 | 11.89% | 9.59% |
| 2019 | 10.85% | 7.53% |
| 2018 | 10.09% | 9.08% |
| 2017 | 9.25% | 32.33% |
| 2016 | 6.99% | -0.85% |
| 2015 | 7.05% | 20.93% |
| 2014 | 5.83% | -13.50% |
| 2013 | 6.74% | 24.58% |
| 2012 | 5.41% | -12.46% |
| 2011 | 6.18% | -10.82% |
| 2010 | 6.93% | -4.55% |
| 2009 | 7.26% | 83.33% |
| 2008 | 3.96% | -167.69% |
| 2007 | -5.85% | -65.20% |
| 2006 | -16.81% | -1,112.65% |
| 2005 | 1.66% | -47.30% |
| 2004 | 3.15% | -30.46% |
| 2003 | 4.53% | -18.23% |
| 2002 | 5.54% | 4.92% |
| 2001 | 5.28% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 10.52% | -99.43% |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -98.75% |
IN
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.